News

Cidara Therapeutics to Showcase Innovations at Upcoming Event

Cidara Therapeutics to Showcase Innovations at Upcoming Event

Cidara Therapeutics to Present at the H.C. Wainwright Conference

Cidara Therapeutics, Inc. (Nasdaq: CDTX) is preparing for a significant presentation at the H.C. Wainwright 26th Annual Global Investment Conference. This biotechnology company is recognized for its cutting-edge approach to developing drug-Fc conjugate (DFC) immunotherapies, utilizing its proprietary Cloudbreak platform. Dr. Jeffrey Stein, the President and CEO, will provide valuable insights into their pioneering work aimed at improving treatment options for serious diseases.

Event Details

The highly anticipated presentation is scheduled for:

Event: H.C. Wainwright 26th Annual Global Conference
Date: Monday, September 9, 2024
Time: 7:00 am ET

Starting from the specified date and time, Cidara's presentation will be available on-demand in the investor section of the company’s official website. This presents an excellent opportunity for stakeholders to gain insights into Cidara's progress and future plans.

About Cidara Therapeutics

With a strong emphasis on developing innovative drug-Fc conjugates, Cidara Therapeutics is making remarkable progress in the pharmaceutical industry. Their leading candidate, CD388, aims to offer long-lasting antiviral prevention against both seasonal and pandemic influenza, presenting a single-dose solution. Recently, CD388 received Fast Track Designation from the FDA, and Cidara is set to launch a Phase 2b clinical trial for this antiviral ahead of the upcoming flu season in 2024.

Innovative Approaches in Oncology

Beyond their virology efforts, Cidara is also extending its DFC platform into the field of oncology. They have recently obtained an Investigational New Drug (IND) allowance for CBO421, which targets CD73 in solid tumors. This development underscores their commitment to creating targeted cancer therapies, thereby enriching the company’s diverse portfolio.

Cidara's Commitment to Patients

Based in San Diego, Cidara Therapeutics is devoted to revolutionizing patient care through its innovative therapies. By concentrating on diseases with significant unmet needs, Cidara strives to enhance patient outcomes and improve quality of life through advanced science and technology.

Looking Ahead

As Cidara prepares for its presentation at this esteemed conference, the insights shared are likely to influence investor perspectives and stakeholder engagement. The advancements in therapeutics, particularly with the promising candidates CD388 and CBO421, are expected to generate interest and support for Cidara’s ongoing research and development efforts.

Frequently Asked Questions

What is Cidara Therapeutics known for?

Cidara Therapeutics specializes in developing innovative drug-Fc conjugate immunotherapies that aim to enhance treatment outcomes for serious diseases.

Who will be presenting at the H.C. Wainwright Conference?

Dr. Jeffrey Stein, the President and CEO of Cidara Therapeutics, will be the featured speaker at the event.

What is the main focus of Cidara's lead candidate, CD388?

CD388 is designed to serve as a long-acting antiviral for the prevention of seasonal and pandemic influenza, requiring only a single administration.

What recent milestones have Cidara achieved?

Cidara's CD388 recently received Fast Track Designation from the FDA, highlighting its potential and paving the way for a Phase 2b trial.

Where is Cidara Therapeutics headquartered?

Cidara Therapeutics is located in San Diego, California, where it conducts its innovative research and development activities.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 347

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
NatGold Pulling NATG From MEXC Amid Security Concerns

Updated Category News Views 427

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Continue Reading
Evaluating GLP-1 Telehealth? Key Questions to Consider

Updated Category News Views 451

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Continue Reading
2027 Toy of the Year Finalists Energize Play Market

Updated Category News Views 272

A Kaleidoscope of Innovation in Toys There's a familiar buzz in the air, folks. The 2027 Toy of the Year Awards finalists have been unveiled, and they're bringing a fresh wave of creativity to children's playrooms. These aren't just toys; they're miniature innovators ready to light up the market this holiday season. The reveal happened at the Chicago Toy & Game Fair and...

Continue Reading
Paris Baguette Pioneers Drive-Thru in Oklahoma

Updated Category News Views 468

Tapping The Unseen Potential In Bakery Cafes Every so often a business move comes along that makes you sit up and say, "Why the hell haven't they done this before?" Paris Baguette has finally cracked that code, rolling out its first-ever drive-thru in Moore, Oklahoma. Now, imagine yourself zipping through for a croissant without leaving the comfort of your car seat. Makes...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 89

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Adding Fireplaces: Home Comfort or Construction Headache?

Updated Category News Views 276

Sizing Up the Installation Options Slapping a fireplace into a home sounds more like a pipe dream than a practical project for most folks. But according to fireplace whiz Jimmy Smith down in North Charleston, the times are a-changin'. These days, with advances in technology, homeowners can actually pull it off without collapsing their living room walls. Nitty-Gritty:...

Continue Reading
FuelCell Faces Class Action Crunch as Deadline Looms

Updated Category News Views 192

FuelCell's Legal Storm: What to Know Now You ever get that feeling when your gut knows it all before you even finish reading the headline? Well, buckle up, because FuelCell Energy, Inc. (NASDAQ:FCEL) is staring down a potential class-action train wreck, and they ain't got much track left to skid on before the deadline hits hard on November 10th, 2026. The Crunchy Details...

Continue Reading
J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Updated Category News Views 174

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

Continue Reading
Boston STEM Expo Sparks Young Minds in Engineering

Updated Category News Views 184

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

Continue Reading

Top 5 Most Recently Viewed Articles

Bio-Thera and Tabuk Join Forces for BAT2206 Biosimilar Launch

Updated Category News Views 136

Bio-Thera Solutions Partners with Tabuk Pharmaceuticals Bio-Thera Solutions Inc. (688177:SH) has announced a significant partnership with Tabuk Pharmaceutical Manufacturing Company, a respected player in the pharmaceutical industry. This collaboration marks a new chapter in the commercialization of BAT2206, a proposed biosimilar to Jansen's Stelara. Understanding BAT2206...

Continue Reading
Unlocking Innovative Trading Solutions with XploraDEX's $XPL

Updated Category News Views 381

XploraDEX: Transforming Trading on the XRP Ledger XploraDEX is on a mission to revolutionize the trading landscape on the XRP Ledger by implementing an intelligent, adaptive decentralized finance (DeFi) infrastructure. With the XRP ecosystem recognized for its remarkable speed and efficiency, many traders have long sought advanced solutions to fully harness its potential....

Continue Reading
Ferrari N.V. Updates on Share Buyback Program Progress

Updated Category News Views 89

Share Buyback Program at a Glance Ferrari N.V. (NYSE/EXM: RACE) has provided an update on its ongoing share buyback program. Launched in 2022 with a total budget of approximately Euro 2 billion, the program is unfolding in tranches designed to support a disciplined capital structure and steady shareholder returns. The continued rollout underscores Ferrari’s intent to...

Continue Reading
Global Ship Lease Announces Generous Dividend for Investors

Updated Category News Views 148

Global Ship Lease Declares Significant Dividend In a noteworthy announcement, Global Ship Lease, Inc. (NYSE:GSL) recently disclosed that its Board of Directors has approved a cash dividend of $0.546875 for each depositary share. Each depositary share represents a 1/100th interest in a share of the Company’s 8.75% Series B Cumulative Redeemable Perpetual Preferred...

Continue Reading
iBio Inc. Showcases Innovative Antibody Developments Soon

Updated Category News Views 194

Exciting Presentations from iBio Inc. iBio, Inc. (NASDAQ: IBIO), a pioneering biotechnology company, is gearing up to present breakthrough research on its Activin E antibody. This development showcases its commitment to addressing critical health challenges like obesity. Recently, Cory Schwartz, Ph.D., the Director of Research and Early Development at iBio, announced his...

Continue Reading